Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
120%(6 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
3
43%
Ph phase_2
4
57%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 33 (42.9%)

Trials by Status

active_not_recruiting114%
terminated114%
completed571%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_3

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871
completedphase_3

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

NCT05514873
completedphase_3

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04115293
terminatedphase_2

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

NCT03225287
completedphase_2

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

NCT03030183
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04225871Phase 3

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Active Not Recruiting
NCT05514873Phase 3

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Completed
NCT04115293Phase 3

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Completed
NCT03225287Phase 2

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Terminated
NCT03030183Phase 2

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

Completed
NCT03078582Phase 2

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Completed
NCT03315130Phase 2

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7